CLNN: Pangali Forward P/E clene.com
Clene Inc. possesses exceptional pricing power over ALS therapy costs due to gold nanoparticles that support neuronal energy. The current research phase, characterized by a lack of sales, places significant pressure on the budget. The company's future P/E multiple visualizes these risks, where 0.00 serves as the base parameter value. This underscores its status as an ambitious developer creating innovative methods to combat neurodegeneration.
Rincian metrik keuangan lan pasar Clene Nanomedicine (CLNN)
- nilai saham lan prakiraan konsensus rega:
- informasi kapitalisasi pasar:
- informasi kapitalisasi buku:
- data tingkat utang lan likuiditas finansial:
Rasio Total Utang marang Ekuitas Clene Inc.|CLNN - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Clene Inc.|CLNN - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Clene Inc|CLNN - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Clene|Indikator likuiditas cepet clene.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
CLNN - Asil keuangan resik|Proyeksi bathi mangsa ngarep Clene Inc.|CLNN - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Clene Inc.|CLNN - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Clene Inc|CLNN - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Clene|CLNN - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan clene.com|CLNN - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Clene Inc.
Analisis dhasar perusahaan:CLNN Clene
To perform high-quality asset selection, an investor must compare current market capitalization with the expected earnings per share for the following year. Analyzing the forward P/E ratio of Clene Inc. (CLNN) allows for an assessment of the cost of future income, which is critical for Clene Inc. (CLNN) amid acute liquidity shortages and a dependence on external financing for nanocatalysts, signaling the risk of overpayment as cash reserves deplete.
Karo sapa Clene Inc. saingan
Rega marang bathi mangsa ngarep Biogen (BIIB)|Rega marang bathi mangsa ngarep NBIX (Neurocrine)|Pangali Forward P/E RGC (Regencell)|Axsome Corp (AXSM) - Rasio prakiraan rega marang bathi|ACAD - Rega marang bathi mangsa ngarep|XENE (xenon-pharma.com) - Rasio rega marang bathi mangsa ngarep|VKTX: Pangali Forward P/E|Rasio prakiraan rega marang bathi Supernus Pharmaceuticals, Inc. (SUPN)|Prakiraan rega marang bathi CPRX|DNLI: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E HRMY|Kapitalisasi marang proyeksi bathi biohavenpharma.com|Rega marang bathi mangsa ngarep Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Rasio rega marang bathi mangsa ngarep|Praxis Medicines - Pangali Forward P/E|Anavex Life Sciences Corp (AVXL) - Prakiraan rega marang bathi|CBLL (CeriBell, Inc.) - Prakiraan rega marang bathi|PRTA - Kapitalisasi marang proyeksi bathi|ALEC (Alector Inc.) - Pangali Forward P/E|Prakiraan rega marang bathi Annexon Biosciences (ANNX)|Rega marang bathi mangsa ngarep Omeros Corporation (OMER)|Rega marang bathi mangsa ngarep NGNE (Neurogene Therapeutics)|Rega marang bathi mangsa ngarep AC Immune ACIU|VYGR: Rasio rega marang bathi mangsa ngarep|NMRA - Rega marang bathi mangsa ngarep|SCLX (Scilex Holding) - Rasio rega marang bathi mangsa ngarep|Tevogen Bio Holdings, Inc. (TVGN) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep ACOG|CGTX (Cognition Therapeutics) - Pangali Forward P/E|Rasio prakiraan rega marang bathi inhibikase.com IKT|Prakiraan rega marang bathi SAVA (Cassava Sciences)|Pangali Forward P/E assertiotx.com (ASRT)|Rega marang bathi mangsa ngarep Coya Therapeutics COYA|Pangali mangsa ngarep rega marang bathi VTGN|OVID - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi acumenpharm.com|CRVO: Pangali Forward P/E|Prakiraan rega marang bathi Alterity Therapeutics Limited|Rega marang bathi mangsa ngarep PepGen Inc|Rega marang bathi mangsa ngarep JUNS|Pangali Forward P/E RLMD|ANVS - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Grace Therapeutics GRCE|AIFF: Rasio rega marang bathi mangsa ngarep|ANEW Medical, Inc. - Pangali Forward P/E|Rasio prakiraan rega marang bathi NeuroSense Therapeutics|RVPH (Reviva Pharmaceuticals) - Prakiraan rega marang bathi|MetaVia - Pangali mangsa ngarep rega marang bathi|NRXS (NeurAxis) - Pangali Forward P/E|Helius Medical Technologies Inc. (HSDT) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Passage Bio, Inc. (PASG)|bionomics.com.au - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E NERV (Minerva Neurosciences)|ATHA - Prakiraan rega marang bathi|ADXN: Prakiraan rega marang bathi|Kapitalisasi marang proyeksi bathi Alzamend Neuro, Inc. ALZN|CYCN: Pangali Forward P/E|Prakiraan rega marang bathi Protagenic Therapeutics, Inc.|Rega marang bathi mangsa ngarep Pasithea Therapeutics Corp|Rega marang bathi mangsa ngarep CRGT|Rega marang bathi mangsa ngarep Avenue Therapeutics, Inc. (ATXI)|Brainstorm Cell Therapeutics Inc. - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Cara Therapeutics, Inc CARA|CHRO: Rasio rega marang bathi mangsa ngarep|ELYM - Rega marang bathi mangsa ngarep|ITCI (Intra-Cellular Therapies) - Rasio rega marang bathi mangsa ngarep|LBPH: Pangali Forward P/E|Rasio prakiraan rega marang bathi Marinus Pharmaceuticals Inc (MRNS)|Prakiraan rega marang bathi NKGN|Pangali Forward P/E NeuroBo Pharma|Rega marang bathi mangsa ngarep Sage Therapeutics, Inc. (SAGE)|SNPX (synaptogen.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Trevena TRVN|Vigil Neuroscience Inc. (VIGL) - Rasio prakiraan rega marang bathi|Anew Medical - Pangali Forward P/E|Cerevel Corp (CERE) - Prakiraan rega marang bathi
